Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 3/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | CETP | P11597 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL260934 | 0.84 | KIF11 (0.47) | KIF11CETPKDM4EMEN1ALDH1A1 | |
| SCHEMBL29942701 | 0.78 | GPR3 (0.47) | KIF11CETP | |
| SCHEMBL78949 | 0.78 | GPR3 (0.47) | KIF11CETP | |
| SCHEMBL2092198 | 0.77 | KIF11 (0.43) | KIF11CETPTRPV1KDM4EMEN1 | |
| SCHEMBL737294 | 0.77 | SLC6A2 (0.38) | KIF11SLC6A2SLC6A4SLC6A3APP | |
| SCHEMBL7386225 | 0.76 | ACHE (0.58) | KIF11SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL678558 | 0.76 | ACHE (0.52) | IDO1KDM4EMEN1ALDH1A1HPGD | |
| SCHEMBL1802320 | 0.76 | CYP3A4 (0.53) | KIF11APPALDH1A1ACHEPOLB | |
| SCHEMBL16952658 | 0.75 | NPC1 (0.43) | KIF11TRPV1MEN1KMT2ACES2 | |
| SCHEMBL5738818 | 0.75 | TP53BP1 (0.43) | TBXA2RTP53BP1MEN1KMT2ACES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| US-7521581-B2 | Catalyst composition and process for producing cross-coupled compound using same | TOSOH CORPORATION (JP) | 2009-04-21 | — | — | US | disclosed |
| EP-1707263-B1 | Catalyst composition comprising an alkylene diamine-nickel complex and process for producing a cross-coupled compound using the same | TOSOH CORP (JP) | 2009-02-25 | — | — | EP | disclosed |
| US-20060224011-A1 | Catalyst composition and process for producing cross-coupled compound using same | TOSOH CORPORATION | 2006-10-05 | — | — | US | disclosed |
| EP-1707263-A1 | Catalyst composition comprising an alkylene diamine-nickel complex and process for producing a cross-coupled compound using the same | Tosoh Corporation (JP) | 2006-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | KIF11 4192/4885SLC6A2 2461/4885SLC6A4 2076/4885 |
| US-20060224011-A1 | Catalyst composition and process for producing cross-coupled compound using same | C5, TST, PYM1 | KIF11 2701/4885SLC6A2 1275/4885SLC6A4 1248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.